(lb) >>10117867 Fauci Rejects Hydroxychloroquine Endorsements: Science Is Not There
Dr. Anthony Fauci: ‘Of Course’ I Would Prescribe Chloroquine to Coronavirus Patients
3/25/2020
https://www.breitbart.com/politics/2020/03/25/dr-anthony-fauci-of-course-i-would-prescribe-chloroquine-to-coronavirus-patients/
Anthony S. Fauci, M.D., H. Clifford Lane, M.D., and Robert R. Redfield, M.D.
This suggests that the overall CLINICAL CONSEQUENCES OF COVID-19 may ultimately be more akin to those of a severe seasonal influenza (which has a case fatality rate of approximately 0.1%) or a pandemic influenza (similar to those in 1957 and 1968) rather than a disease similar to SARS or MERS, which have had case fatality rates of 9 to 10% and 36%, respectively.
Therapy currently consists of supportive care while a variety of investigational approaches are being explored. Among these are the antiviral medication lopin-avir–ritonavir, interferon-1β, the RNA polymerase inhibitor remdesivir, CHLOROQUINE, and a variety of traditional Chinese medicine products.
March 26, 2020
New England Journal of Medicine
https://www.nejm.org/doi/pdf/10.1056/NEJMe2002387
Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future
Chloroquine is a cheap and safe drug that has been used for more than 70 years. In light of the urgent clinical demand, chloroquine phosphate is recommended to treat COVID-19 associated pneumonia in larger populations in the future
*Address correspondence to: Jianjun Gao, Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China
https://www.jstage.jst.go.jp/article/bst/advpub/0/advpub_2020.01047/_pdf
Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 (CloroCOVID19)
In this scenario, the situation of a global public health emergency and evidence about the potential positive effect of chloroquine (CQ) in most coronaviruses, including SARS-CoV-1, and recent data on small trials on SARS-CoV-2, the investigators intend to investigate the efficacy and the safety of CQ diphosphate in the treatment of hospitalized patients with severe acute respiratory syndrome in the scenario of SARS-CoV2. Preliminary in vitro studies and uncontrolled trials with low number of patients of CQ repositioning in the treatment of COVID-19 have been encouraging.
Study Completion Date: June 7, 2020
https://www.clinicaltrials.gov/ct2/show/NCT04323527
Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials
More recent studies have highlighted the possibility of treating patients infected with the novel SARS-CoV-2 virus with chloroquine and hydroxychloroquine, of which mechanism of action is not completely understood. We seek to draw the attention of the scientific community to the possibility of drastically reducing the effects of the virus on the affected patients and improving clinical trials outcome through the synergistic action of zinc and chloroquine in patients suffering from the coronavirus disease.
June 1, 2020
https://pubmed.ncbi.nlm.nih.gov/32335560/
COVID-19: An Update for Pharmacists and Pharmacy Technicians on the Frontlines
Potential Therapeutic Targets in the Coronavirus Life Cycle
Broad entry inhibitors (primarily hydroxychloroquine and chloroquine)
https://www.powerpak.com/course/content/119443